Curesponse
Tel Aviv, Israel· Est.
A functional‑genomic assay that predicts the most effective cancer therapy from a patient’s own tumor tissue.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
A functional‑genomic assay that predicts the most effective cancer therapy from a patient’s own tumor tissue.
Oncology
Technology Platform
A combined genomic‑functional assay that preserves the tumor’s 3‑D structure and micro‑environment to test up to eight therapy options on patient‑specific tissue.
Opportunities
Expansion into additional solid‑tumor indications, reimbursement approval, and deepening collaborations with pharma for companion‑diagnostic development.
Risk Factors
Regulatory clearance for diagnostic use, scalability of tissue culture workflow, and competition from other functional testing platforms.
Competitive Landscape
Competes with organoid and micro‑fluidic assays (e.g., HistoRx, Inivata) but differentiates through a combined genomic‑functional approach that tests multiple therapeutic modalities on a single biopsy.